Clinical Trials on Recurrent Chronic Hepatitis C Virus in Russian Federation

Total 110 results

R-Pharm
Almedis

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Chronic Hepatitis C Genotype 1b

Russian Federation
R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
Biocad

Completed

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

Russian Federation
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Russian Academy of Medical Sciences

Completed

Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection

Liver Diseases | Virus Diseases | Hepatitis | Hepatitis C, Chronic

Russian Federation
AbbVie

Completed

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis (EASY)

Hepatitis C Virus (HCV)

Russian Federation
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

Russian Federation, Sweden
AbbVie

Completed

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2)

Hepatitis C Virus (HCV)

Russian Federation
AbbVie

Completed

Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response (CHOICE)

Hepatitis C Virus (HCV)

Russian Federation
R-Pharm

Completed

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (PIONEER)

Hepatitis C

Russian Federation
AbbVie

Completed

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation (EVEREST)

Chronic Hepatitis C (CHC)

Russian Federation
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation (CITRIN)

Chronic Hepatitis C

Russian Federation
Bristol-Myers Squibb

Completed

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (UNITY 4)

Hepatitis C Virus

Korea, Republic of, Taiwan, Russian Federation
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.

Hepatitis C, Chronic

Russian Federation
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation
Biocad

Completed

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Hepatitis | Hepatitis C

Belarus, Russian Federation, India, Thailand
Center of target therapy

Recruiting

Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA

Chronic Hepatitis D

Russian Federation
Bristol-Myers Squibb

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Hepatitis C

China, Korea, Republic of, Russian Federation
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Intarcia Therapeutics

Completed

Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

Hepatitis C

Russian Federation
Hepatera Ltd.

Completed

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Chronic Viral Hepatitis B With Delta-agent

Russian Federation
Hepatera Ltd.

Completed

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

Chronic Hepatitis B

Russian Federation
Gilead Sciences

Completed

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Hepatitis C

Russian Federation
University of Illinois at Chicago
National Institute on Drug Abuse (NIDA); Prisma Research Center

Completed

Tajik Migrant Health Education Study

HIV Infections | Hepatitis C | Risk Reduction Behavior | Risky Health Behavior

Russian Federation
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
Hoffmann-La Roche

Completed

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Russian Federation
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Hepatera Ltd.
Data Matrix Solutions

Completed

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Chronic Hepatitis D Infection With Hepatitis B

Russian Federation, Germany
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2)

Chronic Hepatitis C

United States, Spain, Italy, Australia, Canada, Poland, Puerto Rico, Russian Federation, Argentina, France, Israel, United Kingdom
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Bristol-Myers Squibb

Completed

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (COMMAND-3)

Hepatitis C

Australia, France, Germany, Italy, United Kingdom, United States, Canada, Poland, Austria, Denmark, Israel, Spain, Russian Federation, Switzerland, Argentina, Brazil
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
GlaxoSmithKline

Completed

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

Cirrhosis, Liver

United States, Taiwan, Germany, Israel, Australia, Singapore, Canada, Czechia, Korea, Republic of, Russian Federation, New Zealand, Romania, Puerto Rico, Malaysia
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
Gilead Sciences

Active, not recruiting

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

Germany, Russian Federation, United States, Italy, Sweden
Hoffmann-La Roche

Completed

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Sweden, United States, Romania, United Kingdom, Denmark, Germany, Russian Federation, Canada, Puerto Rico, Hungary, Poland, Netherlands, Brazil
Bristol-Myers Squibb

Completed

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

Hepatitis C Virus

Australia, France, United States, Spain, Italy, Netherlands, Romania, Russian Federation
GlaxoSmithKline

Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Hepatitis C, Chronic

Puerto Rico, United States, Australia, Germany, Spain, Taiwan, Italy, Belgium, Israel, Korea, Republic of, Canada, France, Russian Federation, India, Greece, Pakistan, Slovakia, Romania, Czech Republic, Poland, Egypt, Ukraine, Brazil
GlaxoSmithKline

Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Hepatitis C, Chronic

Puerto Rico, United States, Australia, Spain, Taiwan, Germany, Italy, Belgium, France, Thailand, Israel, Korea, Republic of, Canada, Netherlands, Russian Federation, Hong Kong, Pakistan, Slovakia, Romania, Poland, United Kingdom, ... and more
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic

Russian Federation
New York University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Computer-based Intervention for Alcohol-using HIV/HCV+ Women

Hepatitis C | Human Immunodeficiency Virus | Alcohol Abuse

United States, Russian Federation
Novartis Pharmaceuticals

Completed

Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Chronic Hepatitis B

Germany, Spain, Austria, Bulgaria, Greece, Turkey, Russian Federation, Italy
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C Virus Infection

United States, Italy, United Kingdom, Germany, Belgium, Russian Federation, New Zealand, Australia

3

Subscribe